EUVIMEDSkopri EUVIMED
FallberichtOpen access · CC BY-NC-ND 4.0

Dermatomyositis‐like skin eruptions under hydroxyurea therapy conceal TP53 ‐mutated atypical keratinocytes: A histopathologic and molecular pathologic case series

Wiebke Pruessmann iD, Jutta Kirfel, Verena-Wilbeth Sailer, Christian Rose iD

Journal of Cutaneous Pathology · 2024

DOI: 10.1111/cup.14690 ↗

At a glance

Fallbericht in Journal of Cutaneous Pathology, 2024. Written by Wiebke Pruessmann and 3 co-authors. Institution: Department of Dermatology, University of Lübeck, Lübeck, Germany. Major MEDLINE topics: Dermatomyositis, Hydroxyurea, Keratinocytes, Tumor Suppressor Protein p53. Cited 2 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Hydroxyurea is an antimetabolite that inhibits DNA synthesis and is used as a treatment option in chronic myeloproliferative disorders. Rarely, “dermatomyositis (DM)‐like” skin lesions are observed after long‐term therapy. In this case series, five skin biopsies of four patients were evaluated by histology, immunohistochemistry, and next‐generation sequencing of the TP53 gene locus. All biopsies showed focal basal pleomorphic keratinocytes and suprabasal aberrant p53 expression as well as sparse to severe vacuolar interface dermatitis. Histopathologically, “DM‐like” skin lesions can be clearly distinguished from DM by marked subepidermal fibrosis, vascular proliferation, and the absence of dermal mucin deposits. In 75% of the specimens multiple, partly inactivating and/or pathogenic point mutations of TP53 were found in low frequencies. “DM‐like” skin eruptions as a long‐term consequence of hydroxyurea therapy are possibly not chemotherapy‐associated benign toxic changes, but rather inflammatory reactions to complex keratinocyte alterations that clinically mimic the picture of DM. Synergistic mutagenic effects of hydroxyurea and sunlight might be responsible for this unique drug side effect and could provide a pathogenic link to the known increased risk of skin cancer in these patients.

Subjects

MeSH terms (MEDLINE)

DermatomyositisHydroxyureaKeratinocytesTumor Suppressor Protein p53HumansDrug EruptionsMutationMyeloproliferative Disorders

Author keywords

TP53 mutationsaltered keratinocytesdermatomyositis‐like skin lesionshydroxyurea

Substances

HydroxyureaTP53 protein, humanTumor Suppressor Protein p53

Authors and institutions

  • Department of Dermatology, University of Lübeck, Lübeck, Germany.
  • Institute of Pathology, University of Lübeck, Lübeck, Germany.
  • Dermatopathology Lübeck, Lübeck, Germany.

ORCID profiles: Wiebke Pruessmann, Christian Rose

Cite

APA

Pruessmann, W., Kirfel, J., Sailer, V. W., & Rose, C. (2024). Dermatomyositis‐like skin eruptions under hydroxyurea therapy conceal TP53 ‐mutated atypical keratinocytes: A histopathologic and molecular pathologic case series. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14690

Vancouver

Pruessmann W, Kirfel J, Sailer VW, Rose C. Dermatomyositis‐like skin eruptions under hydroxyurea therapy conceal TP53 ‐mutated atypical keratinocytes: A histopathologic and molecular pathologic case series. Journal of Cutaneous Pathology. 2024. doi:10.1111/cup.14690

BibTeX
@article{Pruessmann2024,
  author = {Pruessmann, Wiebke and Kirfel, Jutta and Sailer, Verena-Wilbeth and Rose, Christian},
  title = {Dermatomyositis‐like skin eruptions under hydroxyurea therapy conceal TP53 ‐mutated atypical keratinocytes: A histopathologic and molecular pathologic case series},
  journal = {Journal of Cutaneous Pathology},
  year = {2024},
  doi = {10.1111/cup.14690}
}
Start for free →